Abstract
Pulmonary hypertension (PH) is a highly morbid condition without cure. This virtual symposium will explore new therapies beyond vasodilators acting by novel anti-proliferative, antifibrotic, or anti-inflammatory mechanisms to modify the natural history of disease.

Cost:
This event has reduced-rate registration for ACS and NYAS members, at $85 or $30 (for students and post-docs). Please select the appropriate non-member Registration Category and use the Priority Code ACS. Non-members may attend for a fee of $130 (corporate), $105 (non-profit or academic) or $40 (students and post-docs).

For more information and to register for the event, go to: www.nyas.org/PH2021
To become a Member of the New York Academy of Sciences, visit www.nyas.org/benefits

Pulmonary Hypertension: Beyond Vasodilators

Organizers:
Scott MacDonnell, PhD, Regeneron Pharmaceuticals
Yinglin Gao, PhD, Regeneron Pharmaceuticals
Paul B. Yu, MD, PhD, Harvard Medical School, Brigham and Women's Hospital
Elena A. Goncharova, PhD, University of California, Davis
Sonya Dougal, PhD, The New York Academy of Sciences
Barbara Knappmeyer, PhD, The New York Academy of Sciences

Speakers:
Naomi C. Chesler, PhD, University of California, Irvine
Frances de Man, PhD, VU University Medical Center, Amsterdam
Janethe Deolina Oliveira Pena, MD, PhD, Acceleron
Robert Lafyatis, MD, University of Pittsburgh School of Medicine
Tim Lahm, MD, Indiana University School of Medicine
Soni S Pullamsetti, PhD, Max Planck Institute for Heart and Lung Research
Jason Yuan, MD, PhD, University of California San Diego

Date: Tuesday, October 12, 2021
Time: 11:00 AM – 5:30 PM via Webcast

A Joint meeting of the NYACS Biochemical Topical Group and the NYAS Biochemical and Pharmacological Discussion Group